Abametapir
Xeglyze (abametapir) is a small molecule pharmaceutical. Abametapir was first approved as Xeglyze on 2020-07-24. It is used to treat pediculus in the USA. Xeglyze's patents are valid until 2034-12-17 (FDA).
Trade Name | Xeglyze |
---|---|
Common Name | Abametapir |
Indication | pediculus |
Drug Class | Pediculicide, metalloproteinase inhibitor |